What is Gyre Therapeutics, Inc.'s D&A?

Gyre Therapeutics, Inc. (GYRE) reported D&A of $672K in Q1 2026.

How has Gyre Therapeutics, Inc.'s D&A changed year-over-year?

Gyre Therapeutics, Inc.'s D&A increased by 25.6% year-over-year, from $535K to $672K.

What is the long-term trend for Gyre Therapeutics, Inc.'s D&A?

Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s D&A has grown at a 71.0% compound annual growth rate (CAGR), from $290K to $2.48M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Gyre Therapeutics, Inc. GYRE D&A

D&A at other companies

Eli LillyLLY

$509M+9.9%

Madrigal Pharmaceuticals, Inc.MDGL

$386K+1.8%

Theravance BiopharmaTBPH

$381K-7.7%

Rigel PharmaceuticalsRIGL

$597K-1.2%

Zevra Therapeutics, Inc.ZVRA

$368K-77.7%

LQD

Liquidia CorporationLQDA

$497K+10.2%

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s D&A?: Gyre Therapeutics, Inc. (GYRE) reported D&A of $672K in Q1 2026.
How has Gyre Therapeutics, Inc.'s D&A changed year-over-year?: Gyre Therapeutics, Inc.'s D&A increased by 25.6% year-over-year, from $535K to $672K.
What is the long-term trend for Gyre Therapeutics, Inc.'s D&A?: Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s D&A has grown at a 71.0% compound annual growth rate (CAGR), from $290K to $2.48M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.